|Bid||173.65 x 200|
|Ask||173.74 x 100|
|Day's Range||172.42 - 173.87|
|52 Week Range||133.64 - 184.21|
|PE Ratio (TTM)||16.47|
|Dividend & Yield||4.60 (2.67%)|
|1y Target Est||N/A|
Amgen announced that the European Medicines Agency's Committee for Medicinal Products for Human Use has rendered a positive opinion recommending marketing approval of a pediatric formulation of Mimpara for the treatment of secondary hyperparathyroidism
The June 15 short interest data have been compared with the previous report, and short interest in most of the selected biotech stocks increased.
Novartis's generics unit Sandoz said the European Commission approved Erelzi, its biosimilar to Amgen's Enbrel, to treat inflammatory diseases such as rheumatoid arthritis, psoriasis, and psoriatic arthritis. The approval was based on a development programme that demonstrated that Erelzi, a biosimilar of the drug also known as etanercept, matches its reference medicine in terms of safety, efficacy, and quality, Sandoz said in a statement on Tuesday.